Gadoxetic acid disodium (Primovist, BAY86-4873)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Contrast Media
Conditions
Contrast Media
Trial Timeline
May 1, 2009 → Jul 1, 2013
NCT ID
NCT00908596About Gadoxetic acid disodium (Primovist, BAY86-4873)
Gadoxetic acid disodium (Primovist, BAY86-4873) is a approved stage product being developed by Bayer for Contrast Media. The current trial status is completed. This product is registered under clinical trial identifier NCT00908596. Target conditions include Contrast Media.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00908596 | Approved | Completed |
| NCT01411449 | Pre-clinical | Completed |
| NCT00924248 | Pre-clinical | Completed |
| NCT00526188 | Phase 3 | Completed |
Competing Products
11 competing products in Contrast Media
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HRS-9231 + Gadobutrol | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Gadoquatrane (BAY1747846) | Bayer | Phase 3 | 74 |
| GBCAs | Bayer | Pre-clinical | 20 |
| BAY1747846 | Bayer | Phase 1 | 30 |
| Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol | Bayer | Phase 3 | 74 |
| Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol | Bayer | Phase 3 | 74 |
| BAY1747846 + Matching placebo | Bayer | Phase 1 | 30 |
| Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg + Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg + Matching placebo | Bayer | Phase 1 | 30 |
| Gadobutrol (Gadavist/Gadovist, BAY86-4875) | Bayer | Pre-clinical | 20 |
| Iopromide (Ultravist, BAY86-4877) | Bayer | Pre-clinical | 20 |
| Magnevist + Dotarem + Gadovist | Guerbet | Pre-clinical | 15 |